Artelo biosciences receives fda clearance of its ind application for art26.12, a selective fatty acid binding protein 5 inhibitor

Art26.12 seeks to address a critical need in painful neuropathies, including chemotherapy-induced peripheral neuropathy for which there is no fda-approved treatment
ARTL Ratings Summary
ARTL Quant Ranking